
Jennifer Allman
Head, Vehicle Safety Compliance and Product
Analysis

June 14, 2024

Adam Raviv

Chief Counsel
National Highway Traffic Safety Administration
1200 New Jersey Ave., SE,
Room W41-227
Washington, DC 20590

Re: Request for Confidential Treatment of Business Information Submitted Regarding PE24-009

Dear Mr. Raviv

FCA US LLC (f/k/a Chrysler Group LLC) (“FCA US”) is submitting information to the NHTSA Office of Defects Investigation (“ODI”) in connection with the above-referenced investigation.

Based on a careful review of this information, FCA US has determined that some of the information is confidential and should be accorded confidential treatment under this agency’s regulations at 49 C.F.R. Part 512 and Exemption 4 of the Freedom of Information Act (“FOIA”), 5 U.S.C. § 552(b)(4). Therefore, FCA US is submitting the information via secure file transfer, together with this request for confidential treatment and Certificate in Support of Request for Confidentiality, to the Office of Chief Counsel.

The information required by Part 512 is set forth below.

A. Description of the Information (49 C.F.R. § 512.8(a))

The business information for which confidential treatment is being sought is described in the enclosed table found in **Appendix A**.

B. Confidentiality Standard (49 C.F.R. § 512.8(b))

Prior to the Supreme Court’s decision in *Food Marketing Institute v. Argus Leader Media*, 139 S. Ct. 2356 (2019), this submission would have been subject to the confidentiality standard set forth in 49 C.F.R. § 512.15(b) for information that the submitter is required to submit to the agency. The standard for confidential treatment is now set forth in *Food Marketing Institute*, 139 S. Ct. at 2366.

C. Justification for Confidential Treatment (49 C.F.R. § 512.8(c))

FOIA Exemption 4 precludes the disclosure of “trade secrets and commercial or financial information obtained from a person and privileged or confidential.” 5 U.S.C. § 552(b)(4). The information for which FCA US is seeking confidential treatment is clearly “commercial” because it relates to commercial terms in service contracts and the testing and specifications of products that FCA US offers for sale. *See, e.g., Judicial Watch, Inc. v. Export-Import Bank*, 108 F. Supp. 2d 19, 28 (D.D.C.

¹ FCA US has taken steps to assure that the zip files sent via secure file transfer are free of any errors or defects that would prevent NHTSA from opening the files on the files. If, however, the agency is unable to open the files, FCA US respectfully requests that the agency inform FCA US of the issue, so that FCA US may take steps to supply NHTSA’s Office of Chief Counsel with a file that is fully functional.

Mr. Adam Raviv

June 14, 2024

Page -2-

2000). FCA US also is a “person” under the case law governing Exemption 4. *See, e.g., id.*

In *Food Marketing Institute*, the Supreme Court held that information is “confidential” within the meaning of FOIA Exemption 4 when it is “both customarily and actually treated as private by its owner and provided to the government under an assurance of privacy.” 139 S. Ct. at 2366.

FCA US customarily and actually treats the information for which confidential treatment is being requested as private. FCA US makes this information available only to employees, agents, and suppliers who require the information to perform their duties for FCA US and who receive the information with the understanding of their obligations to maintain its confidentiality.

With regard to assurances of privacy, the Supreme Court expressly declined to hold that an assurance is, in fact, a *necessary* condition for confidentiality. *Id.* at 2363. Nor did the Court describe the nature of the “assurances” to which it referred.

In considering the question of assurances, the United States District Court for the District of Columbia repeatedly has concluded that an assurance of confidentiality is *not* required under D.C. Circuit precedent. *See Naumes v. Dep’t of the Army*, 2022 WL 594541, at *8 (D.D.C. Mar. 1, 2022) (“This Circuit does not require assurances of privacy as a separate component of confidentiality, and this Court will not ‘read the word “confidential” to impose a blanket requirement that the government provide an assurance of privacy in every case in which it asserts Exemption 4.’”) (quoting *Renewable Fuels Ass’n v. EPA*, 519 F. Supp. 3d 1, 12 (D.D.C. 2021)); *Cause of Action Inst. v. Export-Import Bank of the U.S.*, 2022 WL 252028, at *18 (D.D.C. Jan. 27, 2022) (stating that the Supreme Court did not resolve whether assurances are a mandatory element of confidentiality under Exemption 4, and “this Court has since explained that binding Circuit precedent compels an answer in the negative”); *Renewable Fuels*, 519 F. Supp. 3d at 12 (declining to require proof of an assurance of confidentiality). At most, according to the D.C. district court, an assurance is “relevant but not strictly required.” *See Wilson v. FCC*, 2022 WL 4245485, at *7 (D.D.C. Sept. 15, 2022) Indeed, “[i]f anything, courts here have taken the position that privately held information is generally confidential absent an express statement by the agency that it would *not* keep information private, or a clear implication to that effect (for example, a history of releasing the information at issue).” *Id.* at *10 (internal quotation marks omitted).

Moreover, even if an assurance of some kind were required under *Food Marketing Institute*, such an assurance need not take the form of a promise by an agency to protect the confidentiality of confidential business information. Although a promise of confidentiality was involved in *Food Marketing Institute*, in ordinary speech, an actual promise need not be made for information to be communicated “under an assurance of privacy.”

The Department of Justice Office of Information Policy (“OIP”) recognized that fact in guidance concerning *Food Marketing Institute*. Specifically, OIP instructed agencies that an *express* assurance of confidentiality is not required. See Exemption 4 After the Supreme Court’s Ruling in *Food Marketing Institute v. Argus Leader Media*, <https://www.justice.gov/oip/exemption-4-aftersupreme-courts-ruling-food-marketing-institute-v-argus-leader-media>, at 5 (second paragraph in subsection headed “Second Condition – Assurance of Confidentiality by Government”) (“[A]n assurance of confidentiality can be either explicit or implicit.”).

As the OIP guidance explains, past agency practice with regard to similar information can suffice for establishing an “implied assurance” of confidentiality. *See id.* (second paragraph under subsection headed “Implied Assurance”) (“Factors to consider include the government’s treatment of similar information For example, an agency’s long history of protecting certain commercial or financial

Mr. Adam Raviv

June 14, 2024

Page -3-

information can serve as an implied assurance to submitters that the agency will continue treating their records in the same manner.”).

Similarly, in *Center for Medical Progress v. U.S. Dep’t of Health & Human Servs.*, 2022 WL 4016617 (D.D.C. Sept. 3, 2022), the court found that there were “implied” assurances of confidentiality (slip op. at *11) based, first, on a government declaration stating that the putative Exemption 4 information had been “‘routinely withheld at [the National Institutes of Health (“NIH”)] and other agencies . . . precisely in recognition of the commercial sensitivity of the information,’” and, second, on a submitter declaration indicating the submitter’s understanding of and reliance upon NIH’s standard practices (*id.*; quoting declaration).

Because the *Critical Mass* voluntary submission standard now governs *all* submissions of information in the D.C. Circuit (*see Renewable Fuels Ass’n*, 519 F. Supp. 3d at 12), NHTSA’s prior practice with regard to *voluntary* submissions provides the relevant standard for whether NHTSA’s past practice provides an assurance of privacy—if an assurance is required at all. In the context of voluntary submissions, NHTSA has consistently accorded confidential treatment to the kinds of records that are being submitted today—that is, tests, service contract summaries, and analysis summaries and descriptions.

Moreover, much of the information that FCA US is submitting today would have qualified for confidential treatment under the substantial-competitive-harm standard that was superseded by *Food Marketing Institute*. Analyses, tests, investigations, and evaluations would, if disclosed, apprise competitors of FCA US’s operational capabilities and enable them to replicate FCA US’s procedures and methodologies without incurring the substantial costs associated with independent development of these procedures and methodologies. Similarly, the release of testing information would enable competitors to develop their own testing capabilities at a fraction of the investments in time and money that would be required for independent development. The designs, diagrams, materials, and specification information contained in these documents would also enable competitors to evaluate and replicate FCA US’s designs, materials, and specifications. Summaries of numbers of service contracts sold could be invaluable to entities that compete in the after-market against FCA US. All of these damaging results of a release of such information have been deemed sufficient to establish substantial competitive harm in the past, when that standard applied.

The competitive harm that would result from a disclosure of the information also is relevant to the reasonable foreseeability of the harm that would result from a disclosure. *See* 5 U.S.C. § 552(a)(8)(A)(i)(I). In the post-*Food Marketing Institute* context, reasonably foreseeable harms sufficient to justify withholding under FOIA Exemption 4 include impairment of the legitimate commercial, financial, business, or research interests of the submitter. *See Naumes*, 2022 WL 594541, at *10.

Accordingly, the confidential treatment of the information that FCA US is submitting is warranted because that information is both customarily and actually treated as private by FCA US and is being provided to the government with an assurance of privacy derived from the expectation that NHTSA will continue its past practice—established both in the voluntary- and compelled-submission contexts—of not disclosing confidential commercial information of the kind at issue here.

D. Class Determination (49 C.F.R. § 512.8(d))

Some of the information subject to this request consists of engineering drawings that satisfy the requirements of paragraph (1) of 49 C.F.R. Part 512, Appendix B.

Mr. Adam Raviv

June 14, 2024

Page -4-

The remaining information for which confidential treatment is sought does not fit within a class determination.

E. Duration for Which Confidential Treatment is Sought (49 C.F.R. § 512.8(e))

FCA US does not anticipate ever adopting a custom of disclosing to the public the kind of information for which confidential treatment is being sought. Therefore, FCA US requests that this information be accorded confidential treatment indefinitely.

F. Contact Information (49 C.F.R. § 512.8(f))

Please direct all inquiries and responses to the undersigned at:

800 Chrysler Drive; CIMS 482-00-83

Auburn Hills, MI 48326

(248) 494-2681


Jennifer.Allman@stellantis.com

The submission includes VINs from which customer identities may be derivable. FCA US assumes that NHTSA will redact these VINs and any other Personal Identifying Information prior to disclosing any of the submitted information to the public.

Enclosed herewith you will also find a Certificate in Support of Request for Confidentiality, signed by an authorized FCA US representative.

If you receive a request for disclosure of the information for which confidential treatment is being sought before you have completed your review of our request, FCA US respectfully requests notification of the request(s) and an opportunity to provide further justification for the confidential treatment of this information, if warranted.

Sincerely,



Jennifer Allman

Enclosures

cc: Mr. Bruce York

Appendix A

<i>Bates page numbers: 6/14/2024 – FCA US LLC – PE24-009 – Compelled – <000001>-<000364></i>			
FILE NAME	<BATES START >	<BATES END>	DESCRIPTION
PE24-009_SERVICE CONTRACTS_CONF BUS INFO.pdf	000001	000054	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
PE24-009_ACTIONS SUMMARY_CONF BUS INFO.pdf	000055	000055	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0001_CONF_BUS_INFO.PDF	000056	000080	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0002_CONF_BUS_INFO.PDF	000081	000105	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0003_CONF_BUS_INFO.PDF	000106	000129	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.

Mr. Adam Raviv

June 14, 2024

Page -6-

Q10_0004_CONF_BUS_INFO.PDF	000130	000153	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0005_CONF_BUS_INFO.pdf	000154	000155	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0006_CONF_BUS_INFO.pdf	000156	000174	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0007_CONF_BUS_INFO.pdf	000175	000176	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0008_CONF_BUS_INFO.pdf	000177	000200	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0009_CONF_BUS_INFO.pdf	000201	000218	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.

Mr. Adam Raviv

June 14, 2024

Page -7-

Q10_0010_CONF_BUS_INFO.PDF	000219	000219	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0011_CONF_BUS_INFO.pdf	000220	000233	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0012_CONF_BUS_INFO.pdf	000234	000238	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0013_CONF_BUS_INFO.PDF	000239	000241	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0014_CONF_BUS_INFO.xlsx	NA	NA	Consists of one .xlsx containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles. The pages for which confidential treatment is being are marked as "ENTIRE PAGE CONFIDENTIAL BUSINESS INFORMATION."
Q10_0015_CONF_BUS_INFO.PDF	000242	000242	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the

			Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0016_CONF_BUS_INFO.PDF	000243	000248	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0017_CONF_BUS_INFO.PDF	000249	000252	Consists of one .PDF containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0018_CONF_BUS_INFO.pdf	000253	000272	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0019_CONF_BUS_INFO.pdf	000273	000280	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0020_CONF_BUS_INFO.pdf	000281	000290	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0021_CONF_BUS_INFO.xlsx	NA	NA	Consists of one .xlsx containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged

			Defect in the Subject Vehicles. The pages for which confidential treatment is being are marked as "ENTIRE PAGE CONFIDENTIAL BUSINESS INFORMATION."
Q10_0022_CONF_BUS_INFO.pdf	000291	000300	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0023_CONF_BUS_INFO.pdf	000301	000311	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0024_CONF_BUS_INFO.pdf	000312	000312	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0025_CONF_BUS_INFO.xlsx	NA	NA	Consists of one .xlsx containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles. The pages for which confidential treatment is being are marked as "ENTIRE PAGE CONFIDENTIAL BUSINESS INFORMATION."
Q10_0026_CONF_BUS_INFO.pdf	000313	000319	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate

			to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0027_CONF_BUS_INFO.pdf	000320	000320	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0028_CONF_BUS_INFO.pdf	000321	000346	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
Q10_0029_CONF_BUS_INFO.xlsx	NA	NA	Consists of one .xlsx containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles. The pages for which confidential treatment is being are marked as "ENTIRE PAGE CONFIDENTIAL BUSINESS INFORMATION."
Q10_0030_CONF_BUS_INFO.pdf	000347	000355	Consists of one .pdf containing entire page confidential business information. This file contains FCA US' summary of information regarding Subject Component change history in the Subject Vehicles.
PE24-009_CHANGE HISTORY_CONF BUS INFO.pdf	000356	000356	Consists of one .pdf containing entire page confidential business information. This file contains a comprehensive compilation of Subject Component part numbers and their corresponding sales by month and year.

Mr. Adam Raviv

June 14, 2024

Page -11-

PE24-009_PART SALES_CONF BUS INFO.pdf	000357	000364	Consists of one .pdf containing entire page confidential business information. This file contains testing and/or analyses of the Subject Component which relate to, or may relate to, the Alleged Defect in the Subject Vehicles.
--	--------	--------	---